Biolegend, 576308, Recombinant Mouse GM-CSF (carrier-free), 500μg

GM-CSF is a hematopoietic factor that is produced by T cells, macrophages, fibroblasts and endothelial cells. This multifunctional cytokine stimulates progenitor cells of neutrophils, eosinophils and macrophages. GM-CSF is also a differentiation and activating factor for granulocytic and monocytic cells.
500μg
Source: Mouse GM-CSF, amino acids Ala18-Lys141 (Accession # NM_009969) was expressed in E. coli.
Molecular Mass: The 125 amino acid N-terminal methionylated recombinant protein has a predicted molecular mass of 14.2 kDa. The DTT-reduced protein migrates at approximately 13 kDa and the non-reduced protein migrates at approximately 11kDa by SDS-PAGE.
Purity: Purity is >98%, as determined by Coomassie stained SDS-PAGE.
Formulation: 0.22 µm filtered protein solution is in 10 mM Sodium Phosphate buffer, 150 mM NaCl, pH 7.2.
Endotoxin Level: Endotoxin level is <0.1 EU/µg (<0.01ng/µg) protein as determined by the LAL method.
Concentration: 10 and 25 µg sizes are bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling: Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
Activity: The ED50 is <0.05 ng/ml, corresponding to a specific activity >2x107 units/mg.
Application: Bioassay
Recommended Usage: Use when high specific biological activity is required.
Application Notes: BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are verified in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at [email protected].
Application References(PubMed link indicates BioLegend citation): Ahn J, et al. 2012. PNAS. 109:19386. PubMed Verhagen J, et al. 2012. PNAS. 110:E221. PubMed Bretscher P, et al. 2015. EMBO Mol Med. 7:593. PubMed
Product Citations: Lin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed Li T, et al. 2022. J Leukoc Biol. 112:845. PubMed Yu H, et al. 2022. Cancer Immunol Res. 10:1095. PubMed Daradoumis J, et al. 2023. Viruses. 15:. PubMed Petenkova A, et al. 2023. Nat Commun. 14:2761. PubMed Rastogi I, et al. 2023. Oncoimmunology. 12:2212550. PubMed Yang N, et al. 2023. Nat Commun. 14:2898. PubMed Kuo PC, et al. 2021. Brain Commun. 3:fcab187. PubMed Chan L, et al. 2022. Cells. 12: . PubMed Teplensky MH, et al. 2023. Nat Biomed Eng. :. PubMed Chan L, et al. 2023. Int J Mol Sci. 24: . PubMed Paris J et al. 2019. Cell Stem Cell. 25(1):137-148 . PubMed Delvecchio FR, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1543. PubMed Ma Q, et al. 2021. Clin Transl Immunology. 10:e1300. PubMed Delbridge ARD, et al. 2021. Front Cell Neurosci. 14:592005. PubMed Bachran C, et al. 2017. Sci Rep.. 10.1038/s41598-017-17948-0. PubMed Xia J, et al. 2020. J Immunol. 205:2077. PubMed Li Y, et al. 2020. Cell Rep. 30:1753. PubMed Chowdhury D, et al. 2019. Cell Rep. 27:3873. PubMed Jin Z, et al. 2020. NPJ Regen Med. 5:19. PubMed Iwashita H, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed Keller CW, et al. 2020. Autophagy. 1:. PubMed Lin W, et al. 2021. Int J Nanomedicine. 16:2775. PubMed Hao Q, et al. 2022. Front Immunol. 13:1011922. PubMed Alban TJ, et al. 2020. Front Immunol. 1.285416667. PubMed Ahn J, et al. 2012. Proc Natl Acad Sci U S A. 109:19386. PubMed Chen X et al. 2017. Cell stem cell. 21(6):747-760 . PubMed Snell LM, et al. 2018. Immunity. 49:678. PubMed Bretscher P, et al. 2015. EMBO Mol Med. 7:593. PubMed Woo YD, et al. 2020. J Allergy Clin Immunol. . PubMed Chen X, et al. 2021. Cell Rep. 37:109991. PubMed Lajqi T, et al. 2020. Front Immunol. 11:546415. PubMed Ayala M, et al. 2017. J Cancer Res Clin Oncol. 10.1007/s00432-017-2421-7. PubMed Becker W, et al. 2021. J Crohns Colitis. 15:1032. PubMed Tian Y, et al. 2021. Front Immunol. 12:761345. PubMed Taylor D, et al. 2022. Front Immunol. 13:936129. PubMed Gogokhia L, et al. 2019. Cell Host Microbe. 25:285. PubMed Xueyang Yu et al. 2017. Immunity. 47(5):903-912 . PubMed Ayala M, et al. 2017. Breast Cancer Res Treat. 10.1007/s10549-017-4414-2. PubMed Stephens WZ, et al. 2021. Cell Rep. 37:109916. PubMed Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed Khan A, et al. 2021. Cell Rep Med. 2:100372. PubMed Moriwaki K, et al. 2021. Mucosal Immunol. Online ahead of print.. PubMed Markworth JF, et al. 2020. JCI Insight. 5:00. PubMed Barrera-Avalos C, et al. 2021. iScience. 24:103520. PubMed Konda P, et al. 2022. Am J Cancer Res. 12:210. PubMed Jain A, et al. 2020. Nat Immunol. 0.920138889. PubMed Nakamura K, et al. 2018. Cancer Cell. 33:634. PubMed Wang Y, et al. 2019. Front Cell Infect Microbiol. 9:286. PubMed
Structure: cytokine
Distribution: T cells, monocytes/macrophages, fibroblasts, endothelial cells, mast cells
Function: Synergistic with IL-1, IL-3, G-CSF; E21R competitive antagonist for receptor binding; stored in ECM with heparan sulfate proteoglycans
Interaction: Granulocyte/macrophage/erythroid/megakaryocytic progenitors, myeloblasts, monoblasts
Ligand/Receptor: Heterodimer GM-CSFR µ subunit (CDw116); β-subunit (CDw131) in common with IL-3R, IL-5R
Bioactivity: Growth/development granulocyte/macrophage progenitors; differentiates myeloblasts/monoblasts; synergizes with Epo proliferation of erythroid/megakaryocytic progenitors
Cell Type: Embryonic Stem Cells, Hematopoietic stem and progenitors
Biology Area: Cell Biology, Stem Cells
Molecular Family: Cytokines/Chemokines, Growth Factors
Antigen References: 1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego. 2. Demetri G, et al. 1991. Blood 78:2791. 3. Fan D, et al. 1991. In vivo 5:571. 4. Negrin R, et al. 1992. Adv. Pharmacol. 23:263.
Gene ID: 12981
UniProt: View information about GM-CSF on UniProt.org
Regulatory Status: RUO
Other Names: Granulocyte/macrophage-colony stimulating factor, CSF-α, Pluripoietin-α, Eosinophil colony stimulating factor (Eo-CSF), Burst promoting activity (BPA)
Q: Why choose BioLegend recombinant proteins?
A: • Each lot of product is quality-tested for bioactivity as indicated on the data sheet.
     • Greater than 95% Purity or higher, tested on every lot of product.
     • 100% Satisfaction Guarantee for quality performance, stability, and consistency.
     • Ready-to-use liquid format saves time and reduces challenges associated with reconstitution.
     • Bulk and customization available. Contact us.
     • Learn more about our Recombinant Proteins.
Q: How does the activity of your recombinant proteins compare to competitors?
A: We quality control each and every lot of recombinant protein. Not only do we check its bioactivity, but we also compare it against other commercially available recombinant proteins. We make sure each recombinant protein’s activity is at least as good as or better than the competition’s. In order to provide you with the best possible product, we ensure that our testing process is rigorous and thorough. If you’re curious and eager to make the switch to BioLegend recombinants, contact your sales representative today!
Q: What is the specific activity or ED50 of my recombinant protein?
A: The specific activity range of the protein is indicated on the product datasheets. Because the exact activity values on a per unit basis can largely fluctuate depending on a number of factors, including the nature of the assay, cell density, age of cells/passage number, culture media used, and end user technique, the specific activity is best defined as a range and we guarantee the specific activity of all our lots will be within the range indicated on the datasheet. Please note this only applies to recombinants labeled for use in bioassays. ELISA standard recombinant proteins are not recommended for bioassay usage as they are not tested for these applications.
Q: Have your recombinants been tested for stability?
A: Our testing shows that the recombinant proteins are able to withstand room temperature for a week without losing activity. In addition the recombinant proteins were also found to withstand four cycles of freeze and thaw without losing activity.
Q: Does specific activity of a recombinant protein vary between lots?
A: Specific activity will vary for each lot and for the type of experiment that is done to validate it, but all passed lots will have activity within the established ED50 range for the product and we guarantee that our products will have lot-to-lot consistency. Please conduct an experiment-specific validation to find the optimal ED50 for your system.
Q: How do you convert activity as an ED50 in ng/ml to a specific activity in Units/mg?
A: Use formula Specific activity (Units/mg) = 10^6/ ED50 (ng/mL)